Related references
Note: Only part of the references are listed.Actionable pharmacogenetic variants in Hong Kong Chinese exome sequencing data and projected prescription impact in the Hong Kong population
Mullin Ho Chung Yu et al.
PLOS GENETICS (2021)
G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19
Jorge E. B. da Rocha et al.
PHARMACOGENOMICS JOURNAL (2021)
CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations-Implication for Drug Safety, Dosing, and Individualized Therapy
Immaculate M. Langmia et al.
FRONTIERS IN GENETICS (2021)
Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
Darshan Mehta et al.
DRUG DISCOVERY TODAY (2020)
A review of clinical pharmacogenetics Studies in African populations
Fouzia Radouani et al.
PERSONALIZED MEDICINE (2020)
In vitro and in vivo human metabolism and pharmacokinetics of S- and R-praziquantel
Nyasha Nicole Kapungu et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Anthracycline induced cardiotoxicity in adult cancer patients: a prospective cohort study from a specialized oncology treatment centre in Uganda
Solomon Kibudde et al.
AFRICAN HEALTH SCIENCES (2019)
Foreword
Luther T. Clark et al.
CURRENT PROBLEMS IN CARDIOLOGY (2019)
Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users
Catherine Chanfreau-Coffinier et al.
JAMA NETWORK OPEN (2019)
Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good
Kristi Krebs et al.
HUMAN GENOMICS (2019)
Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity
Vivian Y. Chang et al.
CURRENT ONCOLOGY REPORTS (2018)
Frequency of CYP2D6 Alleles Including Structural Variants in the United States
Andria L. Del Tredici et al.
FRONTIERS IN PHARMACOLOGY (2018)
Prevalence and associated risk factors for Kaposi's sarcoma among HIV-positive patients in a referral hospital in Northern Tanzania: a retrospective hospital-based study
George P. Semango et al.
BMC CANCER (2018)
Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group
P. C. D. Bank et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development
Iris Rajman et al.
EBIOMEDICINE (2017)
Prioritising the application of genomic medicine
Brett Doble et al.
NPJ GENOMIC MEDICINE (2017)
Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation
Liuh Ling Goh et al.
PLOS ONE (2017)
CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
Seyed Abbas Mirabbasi et al.
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES (2017)
Disease burden and the role of pharmacogenomics in African populations
K. L. Mpye et al.
GLOBAL HEALTH EPIDEMIOLOGY AND GENOMICS (2017)
Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity
Folefac Aminkeng et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBaseA®
Haggar H. Ampadu et al.
DRUG SAFETY (2016)
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans
Katarzyna Drozda et al.
PHARMACOGENETICS AND GENOMICS (2015)
Pharmacogenomic information in drug labels: European Medicines Agency perspective
F. Ehmann et al.
PHARMACOGENOMICS JOURNAL (2015)
Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Kelly E. Caudle et al.
CURRENT DRUG METABOLISM (2014)
Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis
Joyce H. S. You
PHARMACOGENETICS AND GENOMICS (2014)
How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping
Paul Verbeurgt et al.
PHARMACOGENOMICS (2014)
Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
F. Aminkeng et al.
PHARMACOGENOMICS JOURNAL (2014)
Effect of CYP2C19*2 and*17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications
Charlotte Grosdidier et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Kaposi sarcoma trends in Uganda and Zimbabwe: A sustained decline in incidence?
Karima Chaabna et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991-2010
E. Chokunonga et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Characterization of the genetic variation present in CYP3A4 in three South African populations
Britt Drögemöller et al.
Frontiers in Genetics (2013)
Pharmacogenetics in Africa, an Opportunity for Appropriate Drug Dosage Regimens: on the Road to Personalized Healthcare
C. Masimirembwa et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans
Milimo Maimbo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients
Y. Li et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based Map
Rosalind E. Howes et al.
PLOS MEDICINE (2012)
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
Dirk Sibbing et al.
CIRCULATION (2010)
The Canadian Pharmacogenomics Network for Drug Safety: A Model for Safety Pharmacology
Colin J. D. Ross et al.
THYROID (2010)
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium
C. L. Pearce et al.
BRITISH JOURNAL OF CANCER (2009)
Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study
Ushma Mehta et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe
Christopher Nyakutira et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population
Helena Buzkova et al.
CELL BIOCHEMISTRY AND FUNCTION (2008)
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Russell A. Wilke et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SC Sim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men
D Bangsi et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans
A Gaedigk et al.
PHARMACOGENOMICS JOURNAL (2005)
Characterization of the CYP2D6*29 allele commonly present in a blade Tanzanian population causing reduced catalytic activity
A Wennerholm et al.
PHARMACOGENETICS (2001)
Share Paper
